US05338F2074 - Common Stock
0.1414 -0.03 (-16.53%)
After market: 0.1347 -0.01 (-4.74%)
AVALO THERAPEUTICS INC
NASDAQ:AVTX (9/28/2023, 6:29:07 PM)After market: 0.1347 -0.01 (-4.74%)
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. The company is headquartered in Rockville, Maryland and currently employs 20 full-time employees. The company went IPO on 2015-11-13. The firm is focused on the treatment of immune dysregulation by developing therapies that target the Lymphotoxin-like, exhibits Inducible expression, and competes with Herpes Virus Glycoprotein D for Herpesvirus Entry Mediator (HVEM), a receptor expressed by T lymphocytes (LIGHT)-signaling network. Its clinical-stage pipeline includes AVTX-002, AVTX-008, and AVTX-803 programs. AVTX-002 is an Anti-LIGHT monoclonal antibody for treatment of non-eosinophilic asthma, Crohn’s Disease, and COVID-19 acute respiratory distress syndromes. AVTX-008 is a fully human B and T lymphocyte attenuator (BTLA) agonist fusion protein that is being evaluated for several immune dysregulation disorders. AVTX-803 is a monosaccharide therapy for the treatment of leukocyte adhesion deficiency type II (LAD II), which is a congenital disorder of glycosylation (CDG).
AVALO THERAPEUTICS INC
540 Gaither Rd Ste 400
CEO: Michael Cola
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
These stocks are the most active in today's session
Pre-market stock analysis on 2023-09-28: top gainers and losers in today's session.
Curious about the most active stocks on Wednesday? Find out which stocks are dominating the market action!
NEW YORK, NY / NewsDirect / September 27th, 2023 / Best Growth Stocks, a leading independent equity research and corporate access firm focused on finding and reporting on the best growth stocks utilizing exclusive ai-assisted research recently issued an extensive analysis on Avalo Therapeutics Inc a clinical-stage biotechnology company focused on the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network.
As the regular session of the US market on Tuesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
Here you can normally see the latest stock twits on AVTX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.